Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Pulmonary Rehabilitation During Chemotherapy in Stage IIIB/IV Small Cell Lung Cancer

2. november 2026 oppdatert av: dogukan kurc, Istanbul Medipol University Hospital

Pulmonary Rehabilitation During Chemotherapy in Stage IIIB/IV Small Cell Lung Cancer: A Randomized Controlled Trial

This single-center, parallel-group randomized trial evaluated whether adding an 8-week physiotherapist-supervised pulmonary rehabilitation program to a home program improved functional exercise capacity, pulmonary function, and lung cancer symptoms in adults with stage IIIB/IV small cell lung cancer receiving chemotherapy. Thirty participants were randomized 1:1 to 9 scheduled face-to-face rehabilitation contacts plus twice-daily home exercise and comfortable-pace walking for 20 minutes per day, or to a home program of breathing exercises, coughing or huffing, and comfortable-pace walking for 20 minutes per day without face-to-face rehabilitation. Outcomes were assessed at baseline and after 8 weeks. The principal functional outcome for this report was change in 6-minute walk distance; spirometry and the 9-domain Lung Cancer Symptom Scale were exploratory outcomes.

Studieoversikt

Status

Fullført

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

BACKGROUND: Patients with stage IIIB/IV small cell lung cancer receiving chemotherapy can experience deterioration in pulmonary function, exercise capacity, symptoms, and quality of life. Evidence for pulmonary rehabilitation during active chemotherapy remains limited.

STUDY DESIGN: Single-center, parallel-group, open-label randomized controlled trial conducted from November 2018 through May 2019.

SETTING: Oncology Department, Yeditepe University Hospital, Istanbul, Turkey.

ETHICS AND REGISTRATION: The Haliç University Ethics Committee approved the study (No. 109; October 30, 2018), and all participants provided written informed consent before enrollment. The trial was retrospectively registered on April 15, 2026.

PARTICIPANTS: Adults aged 18 years or older with stage IIIB/IV small cell lung cancer, Eastern Cooperative Oncology Group performance status 0-2, active chemotherapy, and no more than 3 completed chemotherapy cycles at enrollment. Participants had to understand the intervention instructions and provide written informed consent. Patients with stage I/II disease or a complication contraindicating pulmonary rehabilitation were excluded.

INTERVENTION GROUP: Nine scheduled face-to-face, physiotherapist-supervised contacts across 8 weeks were used to teach and monitor diaphragmatic and thoracic expansion exercises; postural drainage with percussion when indicated; active-cycle breathing, huffing, and effective coughing; upper- and lower-limb resistance exercises; and walking. The home program was prescribed twice daily, with comfortable-pace walking for 20 minutes per day.

CONTROL GROUP: An 8-week home program of diaphragmatic and thoracic breathing exercises, coughing or huffing, and comfortable-pace walking for 20 minutes per day. The control program did not include face-to-face pulmonary rehabilitation, resistance training, postural drainage or percussion, or active-cycle breathing.

OUTCOMES: Change in 6-minute walk distance from baseline to 8 weeks was designated the principal functional outcome for this report. Exploratory outcomes were forced vital capacity, forced expiratory volume in 1 second, FEV1/FVC, peak expiratory flow, forced expiratory flow at 25%-75% of forced vital capacity, and the 9-domain Lung Cancer Symptom Scale, assessed at baseline and after 8 weeks. No prospectively documented primary-secondary outcome hierarchy was located in the available source records.

Studietype

Intervensjonell

Registrering (Faktiske)

30

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

      • Istanbul, Tyrkia (Türkiye)
        • Yeditepe University Hospital, Oncology Department

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically confirmed small cell lung cancer, Stage IIIB or Stage IV
  • Age 18 years or older
  • Receiving active chemotherapy with no more than 3 completed chemotherapy cycles at enrollment
  • Eastern Cooperative Oncology Group Performance Status 0, 1, or 2
  • Able to understand the intervention instructions
  • Written informed consent provided

Exclusion Criteria:

  • Stage I or Stage II small cell lung cancer
  • Any complication contraindicating pulmonary rehabilitation, including a pathological fracture, open wound, unstable cardiac disease, or active uncontrolled infection
  • Inability or refusal to provide written informed consent

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Supervised Pulmonary Rehabilitation Plus Home Program

Eight-week program with 9 scheduled face-to-face, physiotherapist-supervised contacts. The contacts were used to teach and monitor diaphragmatic and thoracic expansion exercises; postural drainage with percussion when indicated; active-cycle breathing, huffing, and effective coughing; upper- and lower-limb resistance exercises; and walking. The prescribed home program was performed twice daily, with comfortable-pace walking for 20 minutes per day.

Eight-week program with 9 scheduled face-to-face, physiotherapist-supervised contacts. The contacts were used to teach and monitor diaphragmatic and thoracic expansion exercises; postural drainage with percussion when indicated; active-cycle breathing, huffing, and effective coughing; upper- and lower-limb resistance exercises; and walking. The prescribed home program was performed twice daily, with comfortable-pace walking for 20 minutes per day.

Aktiv komparator: Home Breathing, Coughing, and Walking Program

Eight-week home program consisting of diaphragmatic and thoracic breathing exercises, effective coughing or huffing, and comfortable-pace walking for 20 minutes per day. No face-to-face pulmonary rehabilitation, resistance training, postural drainage/percussion, or active-cycle breathing was provided.

Eight-week home program consisting of diaphragmatic and thoracic breathing exercises, effective coughing or huffing, and comfortable-pace walking for 20 minutes per day. No face-to-face pulmonary rehabilitation, resistance training, postural drainage/percussion, or active-cycle breathing was provided.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in 6-Minute Walk Test Distance
Tidsramme: Baseline and Week 8

Functional exercise capacity measured as the distance walked in a 30-meter indoor corridor. Change is calculated as the Week 8 value minus the baseline value and is reported in meters.

Baseline and Week 8

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Change in Peak Expiratory Flow
Tidsramme: Baseline and Week 8

Peak expiratory flow measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters per second.

Baseline and Week 8
Change in FEV1/FVC Ratio
Tidsramme: Baseline and Week 8

FEV1/FVC ratio measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in percentage points.

Baseline and Week 8
Change in Lung Cancer Symptom Scale Domain Scores
Tidsramme: Baseline and Week 8

Nine Lung Cancer Symptom Scale visual analog domains were assessed: appetite, fatigue, cough, dyspnea, hemoptysis, pain, overall lung symptom burden, activities of daily living, and overall quality of life. Scores were recorded on 100-mm visual analog scales and reported on a 0-10 cm scale; lower scores indicate better status. Change is calculated as Week 8 minus baseline, so negative values indicate improvement.

Baseline and Week 8
Change in Forced Expiratory Volume in 1 Second
Tidsramme: Baseline and Week 8

Forced expiratory volume in 1 second measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters.

Baseline and Week 8
Change in Forced Vital Capacity
Tidsramme: Baseline and Week 8

Forced vital capacity measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters.

Baseline and Week 8
Change in Forced Expiratory Flow at 25%-75% of Forced Vital Capacity
Tidsramme: Baseline and Week 8

Forced expiratory flow at 25%-75% of forced vital capacity measured by spirometry. Change is calculated as Week 8 minus baseline and is reported in liters per second.

Baseline and Week 8

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

1. november 2018

Primær fullføring (Faktiske)

30. mai 2019

Studiet fullført (Faktiske)

30. mai 2019

Datoer for studieregistrering

Først innsendt

8. april 2026

Først innsendt som oppfylte QC-kriteriene

8. april 2026

Først lagt ut (Faktiske)

15. april 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

5. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. november 2026

Sist bekreftet

1. august 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • HALIC-EC-109-2018

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

UBESLUTTE

IPD-planbeskrivelse

A de-identified analytic dataset, data dictionary, and reproducible statistical code may be made available by the corresponding author on reasonable request, subject to ethics, institutional, and consent constraints.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .